Table 1 Datasets used in this study.

GSE63332

With bCD, 6 hours after i.d. and i.p. injection

3 (PBS, i.d.) 3 (bCD, i.d.) 3 (PBS, i.p.) 3 (bCD, i.p.)

300 μg (bCD)

Spleen

Mus musculus

8

GSE7768

With LPS and MPL, 6 hours after i.v. injection

3 (PBS, i.v.) 3 (LPS, i.v.) 3 (MPL, i.v.)

10 μg (LPS) 30 μg (MPL)

Spleen

Mus musculus

9

GSE13587

With placebo and HPV-16-L1 VLP on cultured cells

7 (placebo) and 20 (vaccine)

2.5 μg (VLP)

PBMC

Homo Sapiens

13

GSE16879

With IFX infusion in patient with inflammatory bowel disease: UC and CD

12 (healthy) and 61 (disease)

2.0 μg (IFX)

Colon and Ileum mucosa

Homo Sapiens

21